OncoCyte Corporation (OCX) financial statements (2021 and earlier)

Company profile

Business Address 15 CUSHING
IRVINE, CA 92618
State of Incorp. CA
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8228812
Cash and cash equivalents7228810
Short-term investments10012
Receivables0    
Prepaid expense00  0
Other current assets00  0
Other undisclosed current assets1000 
Total current assets:9239913
Noncurrent Assets
Finance lease, right-of-use asset0 
Property, plant and equipment44111
Long-term investments and receivables1311   
Long-term investments1311   
Intangible assets, net (including goodwill)24  11
Goodwill9    
Intangible assets, net (excluding goodwill)15  11
Prepaid expense00   
Deposits noncurrent assets   00
Other noncurrent assets00   
Other undisclosed noncurrent assets420  
Total noncurrent assets:4617122
TOTAL ASSETS:5540101014
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:42111
Accounts payable0000 
Accrued liabilities   11
Employee-related liabilities411  
Other undisclosed accounts payable and accrued liabilities   00
Debt31110
Due to related parties 0223
Other undisclosed current liabilities21101
Total current liabilities:94644
Noncurrent Liabilities
Long-term debt and lease obligation22110
Long-term debt, excluding current maturities2201 
Finance lease, liability00
Capital lease obligations000
Liabilities, other than long-term debt7    
Business combination, contingent consideration, liability7    
Other undisclosed noncurrent liabilities43   
Total noncurrent liabilities:135110
Total liabilities:229665
Stockholders' equity
Stockholders' equity attributable to parent33313410
Common stock157125756046
Accumulated other comprehensive loss   (1)(1)
Accumulated deficit(124)(94)(71)(55)(35)
Total stockholders' equity:33313410
TOTAL LIABILITIES AND EQUITY:5540101014

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues1 0  
Net investment income  0  
Cost of revenue(2)    
Gross profit:(1) 0  
Operating expenses(33)(22)(15)(19)(11)
Other undisclosed operating income (loss)4 (0)  
Operating loss:(30)(22)(15)(19)(11)
Nonoperating expense(1)(0)(1)(1)(0)
Other nonoperating income (expense)0(0)0  
Interest and debt expense(0)(0)(0)  
Loss from continuing operations before equity method investments, income taxes:(31)(22)(16)(19)(11)
Other undisclosed income from continuing operations before income taxes0    
Loss from continuing operations before income taxes:(31)(22)(16)(19)(11)
Income tax benefit1    
Net loss:(30)(22)(16)(19)(11)
Other undisclosed net income attributable to parent 00  
Net loss available to common stockholders, diluted:(30)(22)(16)(19)(11)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(30)(22)(16)(19)(11)
Comprehensive loss:(30)(22)(16)(19)(11)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 00(0)(0)
Comprehensive loss, net of tax, attributable to parent:(30)(22)(16)(20)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: